Following the announcement of positive clinical trial data, CervoMed Inc.(NASDAQ: CRVO) stock price had a stunning spike, rising 147.03% to $5.83. This increased trend follows CRVO’s announcement of encouraging findings from the Phase 2b RewinD-LB research for neflamapimod, its experimental medication used to treat dementia with Lewy bodies (DLB).
Breakthrough Clinical Results Drive Stock Surge
Positive results from the first 16 weeks of the study’s extension phase are highlighted in CervoMed’s most recent statement. The results show notable gains on clinically important endpoints, including the Clinician’s Global Impression of Change (CGIC) and the Clinical Dementia Rating-Sum of Boxes (CDR-SB).
The research also indicated that individuals experienced fewer falls, suggesting that neflamapimod may have a revolutionary effect on DLB, a neurodegenerative disease for which there are presently no FDA-approved therapies in the United States.
Investigation into Prior Study Setbacks
The study’s initial phase faced setbacks, where neflamapimod’s efficacy was less than anticipated. This issue was attributed to the drug’s low plasma concentrations due to a formulation error in the investigational capsules.
However, the new batch of capsules delivered the expected plasma drug levels, leading to significant improvements in clinical metrics, reinforcing the drug’s potential as a viable treatment for DLB.
Future Plans and Regulatory Discussions
CervoMed plans to complete the full 32-week extension phase of the RewinD-LB study and engage with regulatory authorities to finalize the plans for a Phase 3 trial. CRVO aims to use the additional data from the extension phase to strengthen its position and move closer to regulatory approval.
The Phase 2b findings provide strong support for neflamapimod and provide the statistical strength and consistency needed for further clinical development. In dementia research, these findings are unusual as they show a level of clinical improvement that positions neflamapimod as a potential game-changing therapy for dementia with Lewy bodies.
